Medicine :   
Nalidixic acid is a Medicine belongs to Antibacterials group whose properties about Brand can be referenced from   Book : Martindale    Page : 331   Edition : 37,

  ►   Brandname : Diarlop, Gramoneg, Negadix, Negram, Uriben, NegGram

  ►  Doseform : Oral Suspension with   , Tablet with   ,

Reference of this Medicine for its Strength can be taken from   Book : Martindale    Page : 331   Edition : 37,
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral,
Reference :-   Book : Martindale    Page : 331   Edition : 37,

  ►  Indication/uses : Urinary-tract or selected gastrointrestinal infections caused by susceptible Gram-negative bacteria, shigellosis (bacillary dysentery), prophylaxis of urinary-tract infections,
Reference :-   Book : Martindale    Page : 331   Edition : 37,
Dosing of Medicine differ in Adult & Pediatrics ↓


► Nalidixic acid medicine for Adults :

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage   Frequency   Additional Info
1 Antibacterial Oral 900 mg q.i.d. For 7 to 14 days in acute infections, reducing thereafter to half this dose in chronic infections. Since bacterial resistance may develop rapidly it has been suggested that if treatment with nalidixic acid has not resulted in a negative urine culture within 48 hours another antimicrobial should be used.

Ref :-  Book : Martindale    Page : 331   Edition : 37,




For Pediatric :
S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage   Additional Info  
1 Urinary-tract or selected gastrointrestinal infections caused by susceptible Gram-negative bacteria 3 Month Oral 55 60 mg/kg
2 Prophylaxis of urinary-tract infections Oral 30 mg/kg

Ref :- Book : Martindale    Page : 331   Edition : 37,
Precaution :- If a Patient is using 'Nalidixic acid' drug in  thallasemia  disease, then Please Avoid .

►  Side Effect : nausea, vomiting, diarrhoea, abdominal pain, photosensitivity reactions, erythema, bullous eruptions, allergic rashes, pruritus, eosinophilia, fever, angioedema, visual disturbances, headache, Dizziness, vertigo, drowsiness, Confusion, Depression, excitement, hallucinations, haemolytic anaemia, ,
Ref :-   Book : Martindale    Page : 330   Edition : 37,

►  Interaction : Sucralfate , , Probenecid , Chloramphenicol , Nitrofurantoin , Tetracycline , Melphalan , , Warfarin ,
Ref :-   Book : Martindale    Page : 331   Edition : 37,


►  Contraindication : It should be given with care to patients with hepatic or moderate renal impairment, severe cerebral arteriosclerosis, or G6PD deficiency, It should be avoided in infants less than 3 months old., Treatment should be stopped if symptoms of neuropathy or arthralgia occur. Tendon damage may occur rarely and treatment should be stopped if patients experience tendon pain, inflammation, or rupture., Exposure to UV light and excessive exposure to sunlight should be avoided., Nalidixic acid may cause false-positive reactions in urine tests for glucose using copper reduction methods.,
Ref :-   Book : Martindale    Page : 330   Edition : 37,
  ►    Mechanism of Drug Drug Interaction :  The absorption of nalidixic acid is reduced by sucralfate, and divalent and trivalent cations such as aluminium, calcium, iron, magnesium, and zinc, and therefore use of nalidixic acid with antacids, iron preparations, or other preparations containing such cations, whether as active ingredients or excipients, may result in subtherapeutic serum concentrations of the antibacterial. It is recommended that such products should not be given within 2 hours before or after nalidixic acid. The excretion of nalidixic acid is reduced and plasma concentrations increased by probenecid. Other antibacterials such as chloramphenicol, nitrofurantoin, and tetracycline have been shown to antagonise the action of nalidixic acid in vitro and should not be used together. Fatal haemorrhagic enterocolitis has been associated with the use of nalidixic acid and high-dose intravenous melphalan in children; use with other alkylating antineoplastics is also contra-indicated. There is a possible risk of increased nephrotoxicity when nalidixic acid is given with ciclosporin. Nalidixic acid is reported to enhance the effect of oral anticoagulants such as warfarin; this may be due in part to displacement of anticoagulant from its plasma binding sites. The dose of anticoagulant may need to be reduced. ,
Ref :-   Book : Martindale    Page : 331   Edition : 37,


  ►  Mechanism of Action :   Nalidixic acid is considered to act by interfering with the replication of bacterial DNA, probably by inhibiting DNA gyrase (topoisomerase) activity.,
Ref :-   Book : Martindale    Page : 331   Edition : 37,
 ►   

Dietary Products that produce same effect as  Nalidixic acid






►   Route of Elimination :   Renal, Faecal,
Ref :-   Book : Martindale    Page : 331   Edition : 37,


►    Plasma Half-life :   Min value :-   1 hours,    Max value :-   2.5 hours,
Ref :-   Book : Martindale    Page : 331   Edition : 37,


►    Peak Plasma Concentration :   Min value :-   1 hours,    Max value :-   2 hours,
Ref :-   Book : Martindale    Page : 331   Edition : 37,